- Home
- LAW vs TNGX Comparison
LAW vs TNGX Comparison
Compare LAW & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAW
- TNGX
- Stock Information
- Founded
- LAW 2013
- TNGX 2014
- Country
- LAW United States
- TNGX United States
- Employees
- LAW N/A
- TNGX N/A
- Industry
- LAW Computer Software: Prepackaged Software
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LAW Technology
- TNGX Health Care
- Exchange
- LAW Nasdaq
- TNGX Nasdaq
- Market Cap
- LAW 225.0M
- TNGX 248.2M
- IPO Year
- LAW 2021
- TNGX N/A
- Fundamental
- Price
- LAW $4.46
- TNGX $4.26
- Analyst Decision
- LAW Hold
- TNGX Strong Buy
- Analyst Count
- LAW 3
- TNGX 6
- Target Price
- LAW $6.17
- TNGX $12.20
- AVG Volume (30 Days)
- LAW 147.9K
- TNGX 4.9M
- Earning Date
- LAW 05-07-2025
- TNGX 05-12-2025
- Dividend Yield
- LAW N/A
- TNGX N/A
- EPS Growth
- LAW N/A
- TNGX N/A
- EPS
- LAW N/A
- TNGX N/A
- Revenue
- LAW $145,923,000.00
- TNGX $40,990,000.00
- Revenue This Year
- LAW $6.03
- TNGX N/A
- Revenue Next Year
- LAW $6.39
- TNGX N/A
- P/E Ratio
- LAW N/A
- TNGX N/A
- Revenue Growth
- LAW 3.84
- TNGX 10.09
- 52 Week Low
- LAW $3.31
- TNGX $1.03
- 52 Week High
- LAW $6.64
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- LAW 71.66
- TNGX 83.42
- Support Level
- LAW $3.84
- TNGX $2.12
- Resistance Level
- LAW $4.10
- TNGX $3.68
- Average True Range (ATR)
- LAW 0.16
- TNGX 0.61
- MACD
- LAW 0.05
- TNGX 0.23
- Stochastic Oscillator
- LAW 99.23
- TNGX 86.11
About LAW CS Disco Inc.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.